Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Net Revenue	$ 61,302,801	$ 63,388,617
U.S.
Disaggregation of Revenue [Line Items]
Net Revenue	54,792,000	54,385,000
Rest of World
Disaggregation of Revenue [Line Items]
Net Revenue	6,511,000	9,004,000
Drug Revenues
Disaggregation of Revenue [Line Items]
Net Revenue	545,000
Drug Revenues | U.S.
Disaggregation of Revenue [Line Items]
Net Revenue	272,000
Drug Revenues | Rest of World
Disaggregation of Revenue [Line Items]
Net Revenue	273,000
Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	60,758,000	63,116,000
Concentrate Products | U.S.
Disaggregation of Revenue [Line Items]
Net Revenue	54,520,000	54,385,000
Concentrate Products | Rest of World
Disaggregation of Revenue [Line Items]
Net Revenue	6,238,000	8,731,000
Point-in-time | Drug Product Sales
Disaggregation of Revenue [Line Items]
Net Revenue	272,000
Point-in-time | Drug Product Sales | U.S.
Disaggregation of Revenue [Line Items]
Net Revenue	272,000
Point-in-time | Drug Product Sales | Rest of World
Disaggregation of Revenue [Line Items]
Net Revenue	0
Point-in-time | Concentrate Product Sales
Disaggregation of Revenue [Line Items]
Net Revenue	58,778,000	60,995,000
Point-in-time | Concentrate Product Sales | U.S.
Disaggregation of Revenue [Line Items]
Net Revenue	52,540,000	52,264,000
Point-in-time | Concentrate Product Sales | Rest of World
Disaggregation of Revenue [Line Items]
Net Revenue	6,238,000	8,731,000
Point-in-time | Concentrate Product License Fee
Disaggregation of Revenue [Line Items]
Net Revenue	1,980,000	2,121,000
Point-in-time | Concentrate Product License Fee | U.S.
Disaggregation of Revenue [Line Items]
Net Revenue	1,980,000	2,121,000
Point-in-time | Concentrate Product License Fee | Rest of World
Disaggregation of Revenue [Line Items]
Net Revenue	0	0
Over-time | Drug License Fee
Disaggregation of Revenue [Line Items]
Net Revenue	273,000	273,000
Over-time | Drug License Fee | U.S.
Disaggregation of Revenue [Line Items]
Net Revenue	0	0
Over-time | Drug License Fee | Rest of World
Disaggregation of Revenue [Line Items]
Net Revenue	$ 273,000	$ 273,000